Skip to main content
Erschienen in: Hepatology International 2/2011

01.06.2011 | Original Article

Hepatitis C virus infection among patients with non-Hodgkin’s lymphoma in northern India

verfasst von: Subhash Varma, Madhav C. Menon, Ashish Garg, Pankaj Malhotra, Arpita Sharma, Yogesh K. Chawla, Radha K. Dhiman

Erschienen in: Hepatology International | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and aim

Hepatitis C virus (HCV) has been postulated to be an etiological agent for lymphoid malignancies. Whereas a high prevalence of HCV infection in non-Hodgkin’s lymphoma (NHL) patients has been shown to exist in many geographical areas of high HCV prevalence, studies from other parts have not established any form of association. In India, there is a scarcity of data to show either a positive or a negative association between NHL and HCV infection. Therefore, we determined the prevalence of HCV infection in patients with NHL.

Methods

A total of 228 subjects were included, out of which, the number of newly diagnosed consecutive patients with lymphoproliferative disorders (NHL and CLL) were 57 [mean age, 48.7 years (range: 18–80)] and the control group consisted of 171 subjects [mean age, 48.6 years (range: 18–80)]. We used third generation enzyme immunoassay to detect HCV antibodies. HCV RNA was detected by nested RT-PCR.

Results

Among the 57 patients of NHL, 44 (77.2%) had high-grade disease (diffuse large B cell), 6 (10.5%) intermediate-grade (follicular lymphoma), and 7 (12.3%) low-grade (small lymphocytic); 26 patients had B symptoms at diagnosis. None of the patient tested positive for antibody to hepatitis C virus (anti-HCV) while 1 patient (1.75%) tested positive for HCV RNA. Among the age- and sex- matched controls, 2 (1.17%) subjects tested positive for anti-HCV; both were also positive for HCV RNA.

Conclusions

HCV infection is unlikely to be associated with lymphoproliferative disorders in northern India and does not play a major role in the pathogenesis of lymphoproliferative disorders.
Literatur
1.
Zurück zum Zitat Epstein MA, Achong BG. Discovery and general biology of the virus. In Epstein MA, Achong BG, editors. The Epstein-Barr Virus. Berlin: Springer; 1979. Vol 11, 1123–1127 Epstein MA, Achong BG. Discovery and general biology of the virus. In Epstein MA, Achong BG, editors. The Epstein-Barr Virus. Berlin: Springer; 1979. Vol 11, 1123–1127
2.
Zurück zum Zitat Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006;15:2078–2085 Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006;15:2078–2085
3.
Zurück zum Zitat Varma S, Dhiman RK, Srivastava D, et al. Absence of Hepatitis C virus infection among patients with lymphoproliferative disorders in Northern India. Gastroenterology 2004;126:1498–1499 Varma S, Dhiman RK, Srivastava D, et al. Absence of Hepatitis C virus infection among patients with lymphoproliferative disorders in Northern India. Gastroenterology 2004;126:1498–1499
4.
Zurück zum Zitat Nanu A, Sharma SP, Chatterjee K, et al. Marker for transfusion transmissible infection in North India. Voluntary and replacement blood donors. Prevalence and trends, 1989–1996. Vox Sanguinous 1997;73:70–73 Nanu A, Sharma SP, Chatterjee K, et al. Marker for transfusion transmissible infection in North India. Voluntary and replacement blood donors. Prevalence and trends, 1989–1996. Vox Sanguinous 1997;73:70–73
5.
Zurück zum Zitat Duseja A, Arora L, Masih B, Singh H, Gupta A, Behera D, Chawla YK, Dhiman RK. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh. Hepatitis B and C virus—prevalence and prevention in health care workers. Trop Gastroenterol 2002;23:125–126 Duseja A, Arora L, Masih B, Singh H, Gupta A, Behera D, Chawla YK, Dhiman RK. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh. Hepatitis B and C virus—prevalence and prevention in health care workers. Trop Gastroenterol 2002;23:125–126
6.
Zurück zum Zitat Giannoulis E, Economopoulos T, Mandraveli K, et al. The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic Cooperative Oncology Group Study. Acta Haematol 2004;112:189–193 Giannoulis E, Economopoulos T, Mandraveli K, et al. The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic Cooperative Oncology Group Study. Acta Haematol 2004;112:189–193
7.
Zurück zum Zitat Zuckerman E, Zuckerman T, Sahar D Streichman S, Attias D, Sabo E, et al. The effect of antiviral therapy on translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001;97:1555–1559 Zuckerman E, Zuckerman T, Sahar D Streichman S, Attias D, Sabo E, et al. The effect of antiviral therapy on translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001;97:1555–1559
8.
Zurück zum Zitat Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa 2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751–756 Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa 2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751–756
9.
Zurück zum Zitat Sulkowski MS, Emens LA.Regression of splenic lymphoma with villous lymphocytes after treatment of HCV infection. N Engl J Med 2002;347:2168–2170 Sulkowski MS, Emens LA.Regression of splenic lymphoma with villous lymphocytes after treatment of HCV infection. N Engl J Med 2002;347:2168–2170
10.
Zurück zum Zitat Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B cell non-Hodgkin’s lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004;111:1–8 Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B cell non-Hodgkin’s lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004;111:1–8
11.
Zurück zum Zitat Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423–428 Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423–428
12.
Zurück zum Zitat Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B cell non-Hodgkin’s lymphoma: Systematic review and meta-analysis. Gastroenterology 2003;125:1723–1732 Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B cell non-Hodgkin’s lymphoma: Systematic review and meta-analysis. Gastroenterology 2003;125:1723–1732
13.
Zurück zum Zitat Libra M, Polesel J, Russo AE, De Re V, Cinà D, Serraino D, et al. Extrahepatic disorders of HCV infection: a distinct entity of B cell neoplasia? Int J Oncol 2010;36:1331–1340 Libra M, Polesel J, Russo AE, De Re V, Cinà D, Serraino D, et al. Extrahepatic disorders of HCV infection: a distinct entity of B cell neoplasia? Int J Oncol 2010;36:1331–1340
14.
Zurück zum Zitat Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E, et al. Non-Hodgkin’s lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. Int J Cancer 2004;110:380–385 Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E, et al. Non-Hodgkin’s lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. Int J Cancer 2004;110:380–385
15.
Zurück zum Zitat Shirin H, Davidovitz Y, Avni Y, Petchenko P, Krepel Z, Bruck R, Meytes D. Prevalence of HCV infection in patients with lymphoproliferative disorders. Israel Med J 2002;4:24–27 Shirin H, Davidovitz Y, Avni Y, Petchenko P, Krepel Z, Bruck R, Meytes D. Prevalence of HCV infection in patients with lymphoproliferative disorders. Israel Med J 2002;4:24–27
16.
Zurück zum Zitat Salem AK. Prevalence of HCV among Yemeni patients with non-Hodgkin’s lymphoma at AI-Thawra teaching hospital. Gulf J Oncolog 2009;5:22–29 Salem AK. Prevalence of HCV among Yemeni patients with non-Hodgkin’s lymphoma at AI-Thawra teaching hospital. Gulf J Oncolog 2009;5:22–29
17.
Zurück zum Zitat de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, et al. Hepatitis C and non-Hodgkin lymphoma among 4,784 cases and 6,269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451–458 de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, et al. Hepatitis C and non-Hodgkin lymphoma among 4,784 cases and 6,269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451–458
18.
Zurück zum Zitat Spinelli JJ, Lai AS, Krajden M, Andonov A, Gascoyne RD, Connors JM, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer 2008;122:630–633 Spinelli JJ, Lai AS, Krajden M, Andonov A, Gascoyne RD, Connors JM, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer 2008;122:630–633
19.
Zurück zum Zitat Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Abdel-Hamid M, Fahmy A, Strickland GT. Case-control study of non-Hodgkin’s lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004;33:1034–1039 Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Abdel-Hamid M, Fahmy A, Strickland GT. Case-control study of non-Hodgkin’s lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004;33:1034–1039
20.
Zurück zum Zitat Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W, Severson RK, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi- center case-control study. Int J Cancer 2004;111:76–80 Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W, Severson RK, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi- center case-control study. Int J Cancer 2004;111:76–80
21.
Zurück zum Zitat Brind AM, Watson JP, Burt A, Kestevan P, Wallis J, Proctor SJ, Bassendine MF. Non-Hodgkin’s lymphoma and hepatitis C virus infection. Leukemia and lymphoma 1996;21:127–130 Brind AM, Watson JP, Burt A, Kestevan P, Wallis J, Proctor SJ, Bassendine MF. Non-Hodgkin’s lymphoma and hepatitis C virus infection. Leukemia and lymphoma 1996;21:127–130
22.
Zurück zum Zitat Udomsakdi-Auewarakul C, Auewarakul P, Sukpanichnant S, Muangsup W. Hepatitis C virus infection in patients with non-Hodgkins lymphoma in Thailand. Blood 2000;95:3640–3641 Udomsakdi-Auewarakul C, Auewarakul P, Sukpanichnant S, Muangsup W. Hepatitis C virus infection in patients with non-Hodgkins lymphoma in Thailand. Blood 2000;95:3640–3641
23.
Zurück zum Zitat Thalen DJ, Raemaekers J, Galama J, Cooreman MP. Absence of hepatitis C virus infection in non-Hodgkin’s lymphoma. Br J Haematol 1997;96:881–882 Thalen DJ, Raemaekers J, Galama J, Cooreman MP. Absence of hepatitis C virus infection in non-Hodgkin’s lymphoma. Br J Haematol 1997;96:881–882
24.
Zurück zum Zitat Okan V, Yilmaz M, Bayram A, Kis C, Cifci S, Buyukhatipoglu H, Pehlivan M. Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders. Int J Hematol 2008;88:403–408 Okan V, Yilmaz M, Bayram A, Kis C, Cifci S, Buyukhatipoglu H, Pehlivan M. Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders. Int J Hematol 2008;88:403–408
25.
Zurück zum Zitat Sonmez M, Bektas O, Yilmaz M, Durmus A, Akdogan E, Topbas M, et al. The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. Tumori 2007;93:536–539 Sonmez M, Bektas O, Yilmaz M, Durmus A, Akdogan E, Topbas M, et al. The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. Tumori 2007;93:536–539
26.
Zurück zum Zitat Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, et al. High prevalence of hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma in Korea. J Med Virol 2008;80:960–966 Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, et al. High prevalence of hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma in Korea. J Med Virol 2008;80:960–966
27.
Zurück zum Zitat Schöllkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885–1890 Schöllkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885–1890
28.
Zurück zum Zitat Duberg AS, Nordström M, Törner A, Reichard O, Strauss R, Janzon R, et al. Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005;41:652–659 Duberg AS, Nordström M, Törner A, Reichard O, Strauss R, Janzon R, et al. Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005;41:652–659
29.
Zurück zum Zitat Kuniyoshi M, Nakamuta M, Sakai H, Enjoji M, Kinukawa N, Kotoh K, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin’s lymphoma. J Gastroenterol Hepatol 2001;16:215–219 Kuniyoshi M, Nakamuta M, Sakai H, Enjoji M, Kinukawa N, Kotoh K, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin’s lymphoma. J Gastroenterol Hepatol 2001;16:215–219
30.
Zurück zum Zitat Cucuianu A, Patiu M, Duma M, Basarab C, Soritau O, Bojan A, et al. Hepatitis B and C virus infection in Romanian non-Hodgkin’s lymphoma patients. Br J Haematol 1999;107:353–356 Cucuianu A, Patiu M, Duma M, Basarab C, Soritau O, Bojan A, et al. Hepatitis B and C virus infection in Romanian non-Hodgkin’s lymphoma patients. Br J Haematol 1999;107:353–356
31.
Zurück zum Zitat Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745–752 Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745–752
Metadaten
Titel
Hepatitis C virus infection among patients with non-Hodgkin’s lymphoma in northern India
verfasst von
Subhash Varma
Madhav C. Menon
Ashish Garg
Pankaj Malhotra
Arpita Sharma
Yogesh K. Chawla
Radha K. Dhiman
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 2/2011
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9244-9

Weitere Artikel der Ausgabe 2/2011

Hepatology International 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.